10:34 AM EDT, 09/09/2024 (MT Newswires) -- Cytokinetics ( CYTK ) reported Monday its phase 1 study of CK-4021586 met its primary and secondary objectives, supporting the advancement of the drug candidate to a mid-stage trial in patients with heart failure with preserved ejection fraction in Q4.

"The results from this Phase 1 study replicate pre-clinical findings that show CK-586 directly reduces cardiac contractility at the level of the sarcomere," said Chief Medical Officer Stuart Kupfer. "Importantly, CK-586 was observed to have a shallow and predictable PK/PD relationship and half-life that enables a once-daily fixed dosing regimen in patients with HFpEF."

"Preparations are underway for a Phase 2 clinical trial of CK-586 in a subset of patients with HFpEF that we plan to start in the fourth quarter," Kupfer said.

Shares of Cytokinetics ( CYTK ) were up more than 3% in recent trading.

Price: 56.16, Change: +2.07, Percent Change: +3.83